TD Cowen on Ocular Therapeutix (OCUL): 'SOL-1 Data In Q1:2026 Should Be Positive And Clinically Relevant'
Tweet Send to a Friend
TD Cowen analyst Tara Bancroft reiterated a Buy rating and $14.00 price target on Ocular Therapeutix (NASDAQ: OCUL).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
